This meta-analytic review evaluated the effectiveness of depression interventions on the psychological and immunological outcomes of people living with HIV in sub-Saharan Africa. 14 studies, yielding 932 participants were eligible. A random-effects models indicated that depression interventions were followed by large reductions in depression scores (effect size = 1.86, 95% CI = 1.71, 2.01, p < 0.01). No significant effect on immune outcome was observed, however there was a trend toward immune improvement of medium effect size (effect size on CD4 count and/or viral suppression = 0.57, 95% CI = −0.06, 1.20, p = 0.08). Pharmacological interventions appeared to have a significantly larger improvement in depression scores than psychological interventions. The greatest improvement in immune status was demonstrated in psychological treatments which incorporated a component to enhance HIV medication adherence, however these results did not reach significance. Small sample sizes and highly heterogeneous analysis necessitate caution in interpretation. The results of this meta-analysis should thus be treated as preliminary evidence and used to encourage further studies of immunopsychiatry in HIV in sub-Saharan Africa.
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Introduction
Sub-Saharan Africa is the centre of the HIV epidemic, with nearly 26 million people (69% of the global burden) estimated to be infected (UNAIDS, 2016) . Improved access to antiretroviral therapy (ART) (UNAIDS, 2016) is associated with the 34% increase in life expectancy in sub-Saharan Africa over the past 15 years (UNAIDS, 2015) . However, the change in prognosis has revealed vast challenges of this chronic disease endemic in resource limited populations. Major depressive disorder (MDD) is the most common psychiatric manifestation associated with HIV infection (Dubé, 2005) , and one of such challenges. It is twice as common in people living with HIV as in general populations (Chibanda, 2014; Ciesla and Roberts, 2001) , with a prevalence of up to 36% (Gaynes, et al., 2015; Bing, 2001; Els, et al., 1999) , and a treatment gap estimated to be as high as 90% in low and middle income countries (World Health Organisation, 2017) .
The primary aim of this systematic review and meta-analysis was to evaluate the effectiveness of depression interventions on the psychological and immunological outcomes of people living with HIV in subSaharan Africa. The secondary aim was to assess which types of interventions appear to have the largest effect on depression and immunological outcomes.
Aetiology of Major depressive disorder in people living with HIV
Psychological, social and biological factors are all implicated in the aetiology of MDD in HIV (Kinyanda, 2011) . Psychosocial risk factors identified in the sub-Saharan African population include: female gender, older age, unemployment, negative life events, childhood trauma, disability and impaired function, poor social support, low quality of life, life-time attempted suicide, and associated psychiatric illness (Kinyanda, 2011; Olley, 2004) .
The biological aetiology of MDD in people living with HIV is linked, at least in part, to the pro-inflammatory cascade driven by the HIV
